Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
S2CID 28557054
GLP-1 market revenue reaching approximately $52.7 billion in 2025, with projections toward $155.9 billion by 2033 ( [21] )) and the promise of improved health outcomes, the landscape is entering a new phase
All prices include consultation, medication, and shipping
Their ability to fight inflammation also benefits brain and liver health
In addition, exendin-4 treatment repressed mitochondrial dysfunction, as shown by lower levels of the mitochondrial function-associated genes MCU and UCP3, as well as the mitochondrial fission genes DRP1 and FIS1
Athira Pharma (formerly M3 Biotechnology), the WSU spinout founded to commercialize Dihexa-derivative compounds, paid approximately $4 million in a False Claims Act settlement in January 2025 after a whistleblower exposed concealment of the research misconduct from federal grant agencies, and approximately $10 million in a separate class-action settlement to investors
US$ 24.90
US$ 27.06
US$ 27.73
US$ 29.75
US$ 19.99
US$ 22.78
US$ 24.43
